Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 7/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130726 | 0.83 | LRRK2 (0.54) | SMN1; SMN2RXFP1P2RX1LRRK2LMNA | |
| SCHEMBL5060349 | 0.77 | SGMS2 (0.70) | RXFP1P2RX1P2RX7P2RX4LRRK2 | |
| SCHEMBL256456 | 0.73 | LRRK2 (0.63) | LRRK2 | |
| SCHEMBL3277363 | 0.73 | LRRK2 (0.50) | LRRK2 | |
| SCHEMBL256445 | 0.71 | LRRK2 (0.64) | LRRK2 | |
| SCHEMBL14886070 | 0.71 | LRRK2 (0.74) | P2RX1P2RX7P2RX4LRRK2TMPRSS4 | |
| SCHEMBL130386 | 0.71 | LRRK2 (0.62) | P2RX1P2RX7P2RX4LRRK2 | |
| SCHEMBL128623 | 0.70 | P2RX1 (0.60) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL131166 | 0.69 | LRRK2 (0.63) | RXFP1P2RX1LRRK2MEN1KMT2A | |
| SCHEMBL168500 | 0.69 | HPGD (0.49) | SMN1; SMN2SCN9AMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | SMN1; SMN2 4859/4885SCN9A 1072/4885RXFP1 1763/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | SMN1; SMN2 4859/4885SCN9A 1072/4885RXFP1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.